Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-04-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第一届董事会第三十二次会议独立意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding several company matters discussed at the 32nd meeting of the first board of directors. It includes opinions on the 2021 internal control evaluation report, the 2021 profit distribution plan, the 2021 fundraising usage report, 2022 remuneration standards for directors and senior management, and authorization for simplified stock issuance. The content focuses on board-level decisions and approvals rather than full financial statements or detailed financial results. It is not an annual report, audit report, or earnings release. The document is a board/management information announcement about internal control, remuneration, and capital issuance authorizations. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and does not contain full financial data, so it is not a full report but a board meeting opinion document.
2022-04-18 Chinese
2021年度独立董事履职情况报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021年度独立董事履职情况报告" which translates to "2021 Annual Independent Directors' Performance Report". It details the independent directors' activities, attendance, opinions, and oversight during the 2021 fiscal year. The content focuses on governance, board activities, and compliance with laws and internal rules. It does not contain financial statements or audit results, nor is it a transcript or announcement of voting results. It is a report on board/management information specifically about independent directors' duties and performance. The document length is 4427 characters, which is substantial and contains detailed narrative rather than a brief announcement. Therefore, the best fitting category is Board/Management Information (MANG).
2022-04-18 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, governance, environmental and social responsibility, and audited financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial tables, and comprehensive sections typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-18 Chinese
2021年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度董事会审计委员会履职情况报告" which translates to the "2021 Annual Board Audit Committee Performance Report." It details the audit committee's activities, including oversight of financial reports, evaluation of external auditors, internal audit guidance, and internal control assessments for the year 2021. The document includes meeting summaries and audit-related evaluations but does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a standalone report focused on audit committee duties and audit-related information. This fits the definition of an Audit Report / Information (AR) filing, which covers audit reports and related information excluding full annual reports. The document length is 2509 characters, which is relatively short but contains substantive audit committee content rather than just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2021
2022-04-18 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 年年度报告摘要" which translates to "2021 Annual Report Summary." It contains detailed financial data for the year 2021, including total assets, net profit, revenue, and quarterly breakdowns. It also includes company business descriptions, industry analysis, shareholder information, and risk disclosures. The presence of audited financial figures and comprehensive management discussion indicates this is a full annual report rather than a brief announcement or a certification. The document length is over 14,000 characters, supporting that it is a substantive report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-18 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2021年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) regarding the 2021 annual fundraising funds deposit and usage situation of 科兴生物制药股份有限公司. It is issued by the sponsoring institution 中信建投证券股份有限公司. The content details the management, storage, and usage of the fundraising proceeds for the year 2021, including tables of funds usage, bank accounts, and investment projects. It includes audit opinions and compliance with regulatory requirements. The document is a detailed report on the use of raised capital, not a general annual report or earnings release. It is not a mere announcement or certification but a substantive report on fundraising capital usage and compliance. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and results of regulatory checks related to fundraising and capital usage. The document length (13,640 characters) and detailed financial data support this classification with high confidence. FY 2021
2022-04-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.